Measurement of plasma von Willebrand factor in acute coronary syndromes and the influence of ABO blood group status [4]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 2053-2054

  Ray, K K ^a,b   Francis, S ^a   Crossman, D C ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; BLOOD LEVEL; BLOOD SAMPLING; CORONARY ARTERY DISEASE; CORONARY RISK; DEMOGRAPHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE ISCHEMIA; HUMAN; LETTER; LONG TERM CARE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SECRETION; RISK FACTOR; SYMPTOMATOLOGY; WEIBEL PALADE BODY;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; CORONARY DISEASE; HUMANS; VON WILLEBRAND FACTOR;

EID: 13244277485     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00965.x     Document Type: Letter

References (10)

1. Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999; 10: 375-80.
2. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9.
3. Montalescot G, Collet JP, Choussat R, Ankri A, Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients [letter]. Int J Cardiol 2000; 72: 293-4.
4. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
5. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
6. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-8.
7. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
8. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-7.
9. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990; 75: 688-95.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.